• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Definition, assessment and treatment of cognitive impairment associated with schizophrenia: expert opinion and practical recommendations.精神分裂症相关认知障碍的定义、评估与治疗:专家意见及实用建议
Front Psychiatry. 2024 Sep 20;15:1451832. doi: 10.3389/fpsyt.2024.1451832. eCollection 2024.
2
Treatment of Cognitive Impairment Associated with Schizophrenia Spectrum Disorders: New Evidence, Challenges, and Future Perspectives.精神分裂症谱系障碍相关认知障碍的治疗:新证据、挑战与未来展望。
Brain Sci. 2024 Aug 6;14(8):791. doi: 10.3390/brainsci14080791.
3
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders.澳大利亚和新西兰皇家精神科医学院治疗精神分裂症及相关障碍的临床实践指南。
Aust N Z J Psychiatry. 2005 Jan-Feb;39(1-2):1-30. doi: 10.1080/j.1440-1614.2005.01516.x.
4
European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia.欧洲精神病学协会关于精神分裂症认知障碍评估的指南。
Eur Psychiatry. 2022 Sep 5;65(1):e58. doi: 10.1192/j.eurpsy.2022.2316.
5
Pharmacological Treatment of Cognitive Impairment Associated With Schizophrenia: State of the Art and Future Perspectives.精神分裂症相关认知障碍的药物治疗:现状与未来展望
Schizophr Bull Open. 2024 May 23;5(1):sgae013. doi: 10.1093/schizbullopen/sgae013. eCollection 2024 Jan.
6
Clinical and cognitive factors affecting psychosocial functioning in remitted patients with bipolar disorder.影响双相情感障碍缓解期患者心理社会功能的临床和认知因素。
Psychiatriki. 2016 Jul-Sep;27(3):182-191. doi: 10.22365/jpsych.2016.273.182.
7
Deviation from expected cognitive ability is a core cognitive feature of schizophrenia related to neurophysiologic, clinical and psychosocial functioning.与神经生理、临床和社会心理功能相关的精神分裂症的核心认知特征是认知能力的偏离预期。
Schizophr Res. 2020 Jan;215:300-307. doi: 10.1016/j.schres.2019.10.011. Epub 2019 Nov 16.
8
An Update on Treatment of Cognitive Impairment Associated with Schizophrenia.精神分裂症相关认知障碍治疗的最新进展
Curr Top Behav Neurosci. 2023;63:407-436. doi: 10.1007/7854_2022_382.
9
Psychological interventions for psychosis in adolescents.青少年精神病的心理干预措施。
Cochrane Database Syst Rev. 2020 Jul 3;7(7):CD009533. doi: 10.1002/14651858.CD009533.pub2.
10
[Learning potential and cognitive remediation in schizophrenia].[精神分裂症的学习潜能与认知矫正]
Encephale. 2009 Sep;35(4):353-60. doi: 10.1016/j.encep.2008.06.014. Epub 2009 Jan 8.

引用本文的文献

1
Cognitive impairment and its influencing factors in patients with stable schizophrenia on regular medication: a real-world clinical study.规律服药的稳定期精神分裂症患者的认知障碍及其影响因素:一项真实世界临床研究
BMC Psychiatry. 2025 Aug 26;25(1):819. doi: 10.1186/s12888-025-07297-y.
2
Virtual reality interventions for cognitive remediation in severe mental illness.用于严重精神疾病认知康复的虚拟现实干预措施。
Neurosci Appl. 2025 Feb 21;4:105513. doi: 10.1016/j.nsa.2025.105513. eCollection 2025.
3
Differential cognitive and clinical improvements in Schizophrenia and bipolar disorder following hospitalization: A comparative analysis based on the Clock Drawing Test.精神分裂症和双相情感障碍患者住院后的认知与临床差异改善:基于画钟试验的比较分析
PLoS One. 2025 Jul 8;20(7):e0325537. doi: 10.1371/journal.pone.0325537. eCollection 2025.
4
Biomarkers in schizophrenia - past, present and future.精神分裂症中的生物标志物——过去、现在与未来
Rom J Morphol Embryol. 2025 Jan-Mar;66(1):69-79. doi: 10.47162/RJME.66.1.06.
5
Reduced Cerebellar Volumes Associate with P300 Amplitude Attenuation in Children with Clinical High Risk for Psychosis and Early Onset Psychosis.小脑体积减小与临床高危儿童和早发性精神病患者的P300波幅衰减有关。
Cerebellum. 2025 Mar 21;24(3):69. doi: 10.1007/s12311-025-01822-1.
6
Cognitive rehabilitation in schizophrenia research: a bibliometric and visualization analysis.精神分裂症研究中的认知康复:文献计量与可视化分析
Front Psychiatry. 2024 Dec 11;15:1509539. doi: 10.3389/fpsyt.2024.1509539. eCollection 2024.

本文引用的文献

1
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.美国胆碱能毒蕈碱受体激动剂 KarXT(盐酸二甲弗林-托吡酯)治疗精神分裂症的疗效和安全性(EMERGENT-2):一项随机、双盲、安慰剂对照、剂量灵活的 3 期临床试验结果。
Lancet. 2024 Jan 13;403(10422):160-170. doi: 10.1016/S0140-6736(23)02190-6. Epub 2023 Dec 14.
2
Satisfaction with cognitive remediation therapy: its effects on implementation and outcomes using the cognitive remediation satisfaction scale.对认知康复治疗的满意度:使用认知康复满意度量表评估其对实施情况和治疗结果的影响。
Schizophrenia (Heidelb). 2023 Sep 30;9(1):67. doi: 10.1038/s41537-023-00390-9.
3
Life engagement in people living with schizophrenia: predictors and correlates of patient life engagement in a large sample of people living in the community.精神分裂症患者的生活参与度:社区居住的大样本患者生活参与度的预测因素和相关因素。
Psychol Med. 2023 Dec;53(16):7943-7952. doi: 10.1017/S0033291723002106. Epub 2023 Jul 31.
4
Cognitive Effects of Lurasidone and Cariprazine: A Mini Systematic Review.利培酮和卡利拉嗪的认知影响:小型系统评价。
Curr Neuropharmacol. 2023;21(12):2431-2446. doi: 10.2174/1570159X21666230727140843.
5
Insight in cognitive impairment assessed with the Cognitive Assessment Interview in a large sample of patients with schizophrenia.在一项大型精神分裂症患者样本中,使用认知评估访谈评估认知障碍的见解。
Eur Arch Psychiatry Clin Neurosci. 2024 Sep;274(6):1343-1354. doi: 10.1007/s00406-023-01641-7. Epub 2023 Jun 28.
6
Cognitive remediation therapy - implementation and translation into clinical practice in rural and metropolitan New South Wales mental health services.认知矫正治疗 - 在新南威尔士州农村和城市地区心理健康服务中实施和转化为临床实践。
Australas Psychiatry. 2023 Oct;31(5):584-586. doi: 10.1177/10398562231186125. Epub 2023 Jun 26.
7
Implementation of cognitive rehabilitation interventions for schizophrenia in low-income countries: An experience from Togo and Benin.低收入国家精神分裂症认知康复干预措施的实施:多哥和贝宁的经验
Int J Soc Psychiatry. 2024 Mar;70(2):408-409. doi: 10.1177/00207640231181526. Epub 2023 Jun 16.
8
Luvadaxistat: A Novel Potent and Selective D-Amino Acid Oxidase Inhibitor Improves Cognitive and Social Deficits in Rodent Models for Schizophrenia.卢瓦达昔他汀:一种新型强效和选择性 D-氨基酸氧化酶抑制剂,可改善精神分裂症啮齿动物模型的认知和社交缺陷。
Neurochem Res. 2023 Oct;48(10):3027-3041. doi: 10.1007/s11064-023-03956-2. Epub 2023 Jun 8.
9
Shared and distinct abnormalities in sleep-wake patterns and their relationship with the negative symptoms of Schizophrenia Spectrum Disorder patients.精神分裂症谱系障碍患者睡眠-觉醒模式的共同和独特异常及其与阴性症状的关系。
Mol Psychiatry. 2023 May;28(5):2049-2057. doi: 10.1038/s41380-023-02050-x. Epub 2023 Apr 14.
10
Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia.新型 GlyT1 抑制剂 iclepertin(BI 425809)的开发,用于治疗与精神分裂症相关的认知障碍。
Eur Arch Psychiatry Clin Neurosci. 2023 Oct;273(7):1557-1566. doi: 10.1007/s00406-023-01576-z. Epub 2023 Mar 27.

精神分裂症相关认知障碍的定义、评估与治疗:专家意见及实用建议

Definition, assessment and treatment of cognitive impairment associated with schizophrenia: expert opinion and practical recommendations.

作者信息

Vita Antonio, Barlati Stefano, Cavallaro Roberto, Mucci Armida, Riva Marco A, Rocca Paola, Rossi Alessandro, Galderisi Silvana

机构信息

Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

Department of Mental Health and Addiction Services, Azienda Socio-Sanitaria Territoriale (ASST) Spedali Civili of, Brescia, Italy.

出版信息

Front Psychiatry. 2024 Sep 20;15:1451832. doi: 10.3389/fpsyt.2024.1451832. eCollection 2024.

DOI:10.3389/fpsyt.2024.1451832
PMID:39371908
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11450451/
Abstract

A considerable proportion of patients with schizophrenia perform below population norms on standardized neuropsychological tests, and the performance of those performing within normal range is lower than predicted based on parental education. Cognitive impairment predates the onset of psychosis, is observed during symptom remission and in non-affected first-degree relatives of patients. At the present time, cognitive deficits are regarded as key features of schizophrenia, important determinants of poor psychosocial outcome and targets for both pharmacological and non-pharmacological treatment strategies. A group of eight key opinion leaders reviewed and discussed latest advances in scientific research and current good clinical practices on assessment, management, and treatment of CIAS. In the present paper they summarize the current evidence, identify main gaps between current knowledge and mental health services clinical practice, and provide practical recommendations to reduce the gap.

摘要

相当一部分精神分裂症患者在标准化神经心理学测试中的表现低于总体人群标准,而那些表现处于正常范围内的患者的表现也低于基于父母教育程度所预测的水平。认知障碍在精神病发作之前就已出现,在症状缓解期以及患者未受影响的一级亲属中也可观察到。目前,认知缺陷被视为精神分裂症的关键特征、心理社会预后不良的重要决定因素以及药物和非药物治疗策略的靶点。一组八位关键意见领袖回顾并讨论了关于精神分裂症认知障碍评估、管理和治疗的科学研究最新进展以及当前良好临床实践。在本文中,他们总结了当前证据,确定了当前知识与心理健康服务临床实践之间的主要差距,并提供了缩小差距的实用建议。